TTP plc (TTP), a leading independent technology and product development
company, has announced today that it has partnered with Quotient Ltd
(NASDAQ:QTNT), a commercial-stage diagnostics company committed to
transforming transfusion diagnostics and beyond – to develop and
implement a state-of-the-art manufacturing facility for Quotient’s
proprietary MosaiQ™ system.
MosaiQ, Quotient’s proprietary multiplex microarray technology, offers
the world’s first fully automated, consolidated testing platform,
allowing for multiple tests across different modalities. The instrument
is designed to be a game-changing solution, which Quotient believes will
increase efficiencies, improve clinical practice, deliver significant
workflow improvements and operational cost savings to laboratories
around the world.
TTP has been an integral development partner for MosaiQ, providing
extensive technology, science and engineering input to make possible
Quotient’s vision to develop a multiplexed testing platform based on a
custom consumable, including a microarray, and a custom instrument.
TTP initially undertook a product feasibility study and carried this
through to the conception and delivery of a high-volume,
consumable-manufacturing facility. This included the design and
manufacture of a low-cost consumable, development of robust
manufacturing systems, and several bespoke high-volume manufacturing
processes, including microarray printing, array processing and
high-speed assembly, as well as the use of ‘User Centred Design’
research to specify the user requirements of the processing instruments.
Key to the printing of microarrays for this pre-transfusion blood
testing, which includes printed blood cells and antibodies, is SureDrop,
TTP’s bespoke microarray printing technology that has a unique
capability to print a broad range of materials, including cells,
proteins, DNA, and polymers.
The SureDrop print module forms part of the MosaiQ system. To facilitate
Quotient’s requirements, TTP developed a custom-made print module,
incorporating improvements to the technology necessary for this
application, and a high-volume manufacturing line, operating within its
own quality management system, was established at TTP’s Melbourn Science
Park headquarters to ensure the successful delivery of production print
modules.
Earlier this month Quotient announced receipt
of the CE Mark (Conformité Européenne) for its initial
Immunohematology (IH) Microarray for use with its MosaiQ diagnostic
platform.
Phil Rawlins, Programme Manager at TTP, commented: “This has
been an incredibly exciting partnership as Quotient’s MosaiQ platform is
set to radically change the field of blood transfusion typing and
screening. The unique printing capability of SureDrop is a perfect fit
with this application and working with Quotient to commercialise a
high-volume manufacturing system has been extremely rewarding.”
Ed Farrell, President at Quotient, said: “The
multi-disciplinary team at TTP are highly experienced and were able to
rapidly assist us in the manufacturing of MosaiQ to build what is now an
industry leading system. Their expertise, together with their drive to
bring our idea to reality, made them the ideal partner.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20190520005288/en/